Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 05, 2015 10:07 AM ET

Pharmaceuticals

Company Overview of Tensha Therapeutics, Inc.

Company Overview

Tensha Therapeutics, Inc. develops anti-cancer compound for curing acute myeloid leukemia. The company was incorporated in 2011 and is based in Cambridge, Massachusetts.

55 Cambridge Parkway

Suite 102

Cambridge, MA 02142

United States

Founded in 2011

Phone:

617-252-4343

Key Executives for Tensha Therapeutics, Inc.

President and Director
Age: 45
Compensation as of Fiscal Year 2014.

Tensha Therapeutics, Inc. Key Developments

Tensha Therapeutics Announces First Clinical Trial of BET Bromodomain Inhibitor TEN-010 for Treatment of Cancer

Tensha Therapeutics announced that it has begun the first clinical trial of its small molecule, bromodomain and extra-terminal domain (BET) bromodomain inhibitor, TEN-010 for the treatment of cancer. The trial is designed to assess the safety, tolerability and anti-tumor activity of TEN-010 in patients with advanced solid tumors that are refractory or intolerant to standard/approved therapies and NUT midline carcinoma (NMC), a highly aggressive cancer with very limited treatment options. Bromodomains, which are modules contained within epigenetic proteins, play critical roles in influencing gene transcription by functioning as 'readers' of epigenetic marks. Once bound to chromatin, these bromodomain-containing proteins can influence gene expression. Tensha's Founder, James Bradner, MD, an Assistant Professor at Harvard Medical School and Investigator at the Dana-Farber Cancer Institute, was the first to recognize the broad potential of small molecule BET bromodomain inhibitors across a range of therapeutic areas. Dr. Bradner's seminal work identified NMC as sensitive to BET bromodomain inhibition. NMC is a rare, invariably fatal cancer caused in the majority of cases by a gene translocation event that results in the expression of the NUT protein fused to the BET bromodomains of BRD3 or BRD4. Subsequent studies from Dr. Bradner's and collaborating laboratories have established BET bromodomain inhibition as a therapeutic strategy to target Myc overexpression and demonstrated the potential of this approach to other cancers, including multiple myeloma, acute myeloid leukemia, non-small cell lung cancer and neuroblastoma.

Similar Private Companies By Industry

Company Name Region
Citra Anticoagulants Inc. United States
Voyager Therapeutics, Inc. United States
Theregen, Inc. United States
Yasoo Health Inc. United States
HerbalScience Group LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Tensha Therapeutics, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.